Inhibrx Ano de IPO
Qual é o Ano de IPO de Inhibrx?
O Ano de IPO de Inhibrx, Inc. é 2020
Qual é a definição de Ano de IPO?
A oferta pública inicia (OPI)l é um tipo de oferta pública em que as ações de uma empresa geralmente são vendidas a investidores institucionais que, por sua vez, vendem para o público em geral, em uma bolsa de valores, pela primeira vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Ano de IPO de empresas na Setor Health Care em NASDAQ em comparação com Inhibrx
O que Inhibrx faz?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas com ano de ipo semelhantes a Inhibrx
- Acusensus Ltd tem Ano de IPO de 2019
- Grayscale Ethereum Trust (ETH) tem Ano de IPO de 2019
- Powerwrap Ltd tem Ano de IPO de 2019
- Powerwrap tem Ano de IPO de 2019
- National Rural Utilities Cooper tem Ano de IPO de 2019
- Listed Funds Trust tem Ano de IPO de 2019
- Inhibrx tem Ano de IPO de 2020
- Globally Local Technologies tem Ano de IPO de 2021
- uniQure N.V tem Ano de IPO de 2021
- Trustpilot plc tem Ano de IPO de 2021
- IQVIA tem Ano de IPO de 2021
- ACTIA S.A tem Ano de IPO de 2021
- Remark tem Ano de IPO de 2021